ABEONA THERAPEUTICS INC.
Business
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening genetic diseases. The company's lead product, ZEVASKYN® (prademagene zamikeracel), is an FDA-approved autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds, manufactured at its cGMP facility in Cleveland, Ohio and administered through a network of qualified treatment centers. The pipeline includes AAV-based gene therapies for ophthalmic diseases (ABO-503, ABO-504, ABO-505) using proprietary AIM™ capsid technology, with programs in development or out-licensed for additional rare genetic indications.
Summary from 10-K filed 2026-03-17
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 6 | — | 4 | 1 | 3 | |
| Cost of sales | 2 | — | — | — | — | |
| Royalties | 2 | — | 2 | 450,000 | — | |
| Research and development | 27 | 34 | 31 | 29 | 39 | |
| Selling, general and administrative | 65 | 30 | — | — | — | |
| Total costs and expenses | 95 | 64 | — | — | — | |
| Loss from operations | −89 | −64 | −47 | −51 | −90 | |
| Interest income | 6 | 4 | 2 | 431,000 | 40,000 | |
| Interest expense | −4 | −4 | −418,000 | −736,000 | −4 | |
| Change in fair value of warrant and derivative liabilities | 6 | −755,000 | −12 | 11 | — | |
| Gain from sale of priority review voucher, net | 152 | — | — | — | — | |
| Other income, net | 410,000 | 1 | 3 | 141,000 | — | |
| Income (loss) before income taxes | 71 | −64 | — | — | — | |
| Income tax (benefit) expense | 100,000 | — | — | — | — | |
| Net income (loss) | 71 | −64 | −54 | −40 | −85 | |
| Basic income (loss) per common share | 1.34 | −1.55 | −2.53 | −5.53 | −21.57 | |
| Dilutive income (loss) per common share | 1.01 | −1.55 | −2.53 | −5.53 | — | |
| Basic | 53 | 41 | 21 | 8 | 4 | |
| Dilutive | 66 | 41 | 21 | 8 | — | |
| Change in unrealized gains related to available-for-sale debt securities | 130,000 | 74,000 | 34,000 | −99,000 | 9,000 | |
| Comprehensive income (loss) | 71 | −64 | −54 | −44 | −85 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 78 | 23 | 14 | 14 | 33 | |
| Short-term investments | 113 | 74 | 38 | 38 | 12 | |
| Restricted cash | — | 338,000 | 338,000 | 338,000 | 6 | |
| Accounts receivable, net | 6 | — | — | — | 3 | |
| Inventory | 5 | — | — | — | — | |
| Other receivables | 568,000 | 2 | 2 | 188,000 | — | |
| Prepaid expenses and other current assets | 1 | 1 | 729,000 | 424,000 | 2 | |
| Total current assets | 205 | 101 | 56 | 53 | 56 | |
| Property and equipment, net | 10 | 4 | 4 | 6 | 12 | |
| Operating lease right-of-use assets | 4 | 4 | 4 | 5 | 9 | |
| Other assets | 781,000 | 96,000 | 277,000 | 43,000 | — | |
| Total assets | 220 | 109 | 64 | 64 | 80 | |
| Accounts payable | 8 | 3 | 2 | 2 | 4 | |
| Accrued expenses | 8 | 6 | 6 | 4 | 6 | |
| Current portion of long-term debt | 12 | 6 | — | — | — | |
| Current portion of operating lease liability | 864,000 | 823,000 | 998,000 | 2 | 2 | |
| Accrued taxes | 126,000 | — | — | — | — | |
| Other current liabilities | 2,000 | 64,000 | 1,000 | 204,000 | 296,000 | |
| Total current liabilities | 30 | 17 | 13 | 8 | 17 | |
| Long-term operating lease liabilities | 4 | 3 | 4 | 6 | 8 | |
| Long-term debt | 8 | 13 | — | — | — | |
| Warrant liabilities | 19 | 32 | — | — | — | |
| Total liabilities | 60 | 65 | 49 | 37 | 37 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — | — | — | — | |
| Common stock - $0.01 par value; authorized 200,000,000 shares; 55,043,413 and 45,644,091 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 550,000 | 457,000 | 265,000 | 177,000 | 1 | |
| Additional paid-in capital | 901 | 857 | 764 | 722 | 697 | |
| Accumulated deficit | −742 | −813 | −750 | −695 | −656 | |
| Accumulated other comprehensive loss | 138,000 | 8,000 | −66,000 | −129,000 | −27,000 | |
| Total stockholders equity | 159 | 44 | 15 | 27 | 42 | |
| Total liabilities and stockholders equity | 220 | 109 | 64 | 64 | 80 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 3 | 2 | 2 | 3 | 3 | |
| Stock-based compensation expense | 11 | 7 | 5 | 3 | — | |
| Accretion and interest on short-term investments | 889,000 | 276,000 | −93,000 | −380,000 | 122,000 | |
| Amortization of right-of-use lease assets | 1 | 903,000 | 910,000 | 1 | 1 | |
| Non-cash interest | 1 | 2 | 417,000 | — | — | |
| Gain on disposal of property and equipment | — | −2,000 | 47,000 | 100,000 | — | |
| Gain from sale of priority review voucher | −152 | — | — | — | — | |
| Accounts receivable | −6 | — | — | 3 | −3 | |
| Inventory | −5 | — | — | — | — | |
| Other receivables | 1 | 792,000 | −2 | −188,000 | — | |
| Prepaid expenses and other current assets | −151,000 | −564,000 | −155,000 | 2 | 331,000 | |
| Other assets | −685,000 | 181,000 | −234,000 | 125,000 | −7,000 | |
| Accounts payable and accrued expenses | 7 | 2 | 2 | −4 | 825,000 | |
| Accrued taxes | 126,000 | — | — | — | — | |
| Lease liabilities | −576,000 | −1 | −1 | −1 | — | |
| Change in payable to licensor | — | −5 | — | −5 | −16 | |
| Other current liabilities | −85,000 | 16,000 | −203,000 | −292,000 | — | |
| Net cash used in operating activities | −76 | −56 | −37 | −43 | −66 | |
| Proceeds from sale of priority review voucher, net of transaction costs of $2.6 million | 152 | — | — | — | — | |
| Capital expenditures | −8 | −2 | −331,000 | −130,000 | −4 | |
| Proceeds from disposal of property and equipment | — | 18,000 | 204,000 | 2 | — | |
| Purchases of short-term investments | −207 | −157 | −52 | −78 | −20 | |
| Proceeds from maturities of short-term investments | 167 | 120 | 52 | 53 | 90 | |
| Net cash provided by (used in) investing activities | 105 | −39 | 208,000 | −24 | 66 | |
| Proceeds from ATM sales of common stock, net of issuance costs | 17 | 15 | 14 | 13 | 8 | |
| Payments related to net settlement of restricted share awards | −37,000 | −526,000 | −182,000 | −5,000 | — | |
| Proceeds from underwritten sales of common stock, net of issuance costs | — | 70 | — | — | — | |
| Proceeds from exercise of warrants | 9 | — | — | — | — | |
| Proceeds from issuance of long-term debt | — | 20 | — | — | — | |
| Payment of debt issuance costs | — | −963,000 | −150,000 | — | — | |
| Net cash provided by financing activities | 26 | 104 | 37 | 43 | 25 | |
| Net increase in cash, cash equivalents and restricted cash | 55 | 9 | 256,000 | −24 | 25 | |
| Right-of-use asset obtained in exchange for new operating lease liabilities | 1 | — | 419,000 | — | — | |
| Derivative and warrant additions associated with loan and security agreement | 80,000 | 1 | — | — | — | |
| Reclassification of derivative and warrant liability to equity | 7 | 1 | — | — | — | |
| Changes in accrued property and equipment | −406,000 | 471,000 | — | — | — | |
| Cash paid for interest | 3 | 3 | — | — | — | |
| Cash paid for taxes | — | 7,000 | 14,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ABEONA THERAPEUTICS INC.'s CIK number?
ABEONA THERAPEUTICS INC.'s SEC CIK number is 0000318306 (318306). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ABEONA THERAPEUTICS INC.'s SEC filings?
All of ABEONA THERAPEUTICS INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ABEONA THERAPEUTICS INC. last report earnings?
ABEONA THERAPEUTICS INC. (ABEO) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-022610). This is ABEONA THERAPEUTICS INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ABEONA THERAPEUTICS INC.'s most recent earnings 8-K?
ABEONA THERAPEUTICS INC.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001493152-26-022610. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ABEONA THERAPEUTICS INC.'s latest earnings 8-K →
Look up any company's CIK number →